Aurora Cannabis reported Q2 2027 financial results, including C$86.0 million in net revenue and C$14.0 million in adjusted EBITDA. The company also announced the cancellation of its investor conference due to its pending acquisition by Organigram Global, indicating the acquisition is proceeding as planned.
Aurora Cannabis reported its Q2 2027 financial results, showing C$86.0 million in revenue and C$14.0 million in adjusted EBITDA. The key development, however, is the cancellation of its investor conference due to the previously announced acquisition by Organigram Global. This confirms the acquisition is moving forward, which is significant for both companies and their investors. For ACB, these results are likely secondary to the acquisition news, while for OGI, it provides an update on the target company's performance ahead of the merger. The short-term implication is a confirmation of the acquisition's progress, while the long-term implications involve the combined entity's market position and financial performance. A key opportunity for traders is to assess the combined value proposition and potential synergies from the merger.